Products
Metelimumab Biosimilar Monoclonal Antibody (TGFB1) for Research
Anti-TGFB1 therapeutic antibody (Pre-made Metelimumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma.[1] It was dropped from further development in favour of fresolimumab,[2] which was being developed by Genzyme as of 26.[3]
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-908-1mg | 1mg | 3090 |
| GMP-Bios-INN-908-10mg | 10mg | |
| GMP-Bios-INN-908-100mg | 100mg | |
| GMP-Bios-INN-908-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Metelimumab Biosimilar, Whole Mab, Anti-Tgfb1 Antibody: Anti-CED/DPD1/IBDIMDE/LAP therapeutic antibody |
| INN Name | Metelimumab |
| Target | TGFB1 |
| Format | Whole mAb |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | IgG4 - kappa |
| VD LC | IgG4 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Genzyme Corp. (Cambridge MA USA) / Cambridge Antibody Technology (Cambridge UK) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
